SCHEMBL9933427

SCHEMBL9933427

O=C(O)N1C[C@@H]2C(c3noc(C4CC4)n3)[C@@H]2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.38
HCRTR2 O43614 2/20 0.38
CPT1A P50416 3/20 0.36
HSD11B1 P28845 6/20 0.36
CPT2 P23786 2/20 0.35
SMYD3 Q9H7B4 2/20 0.35
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33
TUBA3E Q6PEY2 1/20 0.33
TUBA1A Q71U36 1/20 0.33
TUBA1C Q9BQE3 1/20 0.33
TUBB6 Q9BUF5 1/20 0.33
TUBB2B Q9BVA1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9933425 1.00 HCRTR1 (0.38) HCRTR1HCRTR2CPT1AHSD11B1CPT2
SCHEMBL9965905 0.80 NR1H2 (0.36) HCRTR1HCRTR2CPT1ACPT2
SCHEMBL9963084 0.80 NR1H2 (0.36) HCRTR1HCRTR2CPT1ACPT2
SCHEMBL9933638 0.79 CCR5 (0.34) DPP4
SCHEMBL9933637 0.79 CCR5 (0.34) DPP4
SCHEMBL2023091 0.79 TUBB4A (0.42) HCRTR1HCRTR2CPT1AHSD11B1CPT2
SCHEMBL22194735 0.75 TRPA1 (0.36)
SCHEMBL22194734 0.75 TRPA1 (0.36)
SCHEMBL22194731 0.75 TRPA1 (0.36)
SCHEMBL9934284 0.74 HCRTR1 (0.40) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HCRTR1 484/4885HCRTR2 388/4885CPT1A 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.